Healthcare / Drug Manufacturers - GeneralShanghai
$5.08
+0.11 (+2.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.6B · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.6B
P/E
12.4x
↓EV/EBITDA
5.9x
↓ROE
8.7%
↑Gross Margin
6.2%
↓Debt/Equity
0.81
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.1%
FCF CAGR
—
FCF margin
-0.3%
FCF / Net income
-0.26x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $54.96B · net income $624.8M · FCF $-159.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $54.96B | $54.96B | $53.70B | $53.59B | $50.22B |
| Net Income | $624.8M | $624.8M | $570.6M | $577.8M | $595.7M |
| EBITDA | $1.74B | $1.74B | $1.60B | $1.63B | $1.50B |
| EPS | 0.43 | 0.43 | 0.44 | 0.45 | 0.47 |
| Gross Margin | 6.2% | 6.2% | 6.3% | 6.2% | 6.5% |
| Operating Margin | 2.8% | 2.8% | 3.0% | 2.8% | 3.0% |
| Net Margin | 1.1% | 1.1% | 1.1% | 1.1% | 1.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.81 | 0.81 | 1.24 | 0.98 | 0.93 |
| Current Ratio | 1.45 | 1.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-159.6M | $-159.6M | $1.59B | $1.75B | $-837.6M |
| Returns | |||||
| ROE | 8.7% | 8.7% | 8.3% | 9.0% | 9.9% |
| Valuation | |||||
| P/E | 12.39 | 12.39 | 10.73 | 11.01 | 10.93 |
| EV/EBITDA | 5.88 | 5.88 | 6.28 | 6.33 | 6.53 |
| P/B | 1.04 | 1.04 | 0.90 | 0.99 | 1.08 |
| Growth & Yield | |||||
| Revenue Growth | 2.4% | 2.4% | 0.2% | 6.7% | — |
| EPS Growth | -2.7% | -2.7% | -1.6% | -6.3% | — |
| Dividend Yield | 3.3% | 3.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
1.9%
EPS terminal req.
$0.45
Spread vs growth
-4.6%
5Y implied EPS CAGR
5.1%
EPS terminal req.
$0.55
Spread vs growth
-7.8%
10Y implied EPS CAGR
7.5%
EPS terminal req.
$0.88
Spread vs growth
-10.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+2.5%
Start / end P/E
11.8x → 12.0x
EPS bridge
0.44 → 0.43
Residual
-0.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.